Form 4: Vera Therapeutics Director Buys $250K in Stock

Vera Therapeutics Director Patrick G. Enright acquired 5,882 shares of Class A Common Stock for $42.50 per share, signaling confidence in the company.

Summary

• Patrick G. Enright, a Director of Vera Therapeutics, Inc. (VERA), purchased 5,882 shares of Class A Common Stock.
• The transaction occurred on December 11, 2025, at a price of $42.50 per share.
• The total value of the direct acquisition was approximately $250,035.
• Following this transaction, Enright directly owns 5,882 shares.
• Enright also has indirect beneficial ownership of 1,797,619 shares through Longitude Prime Fund, L.P. and 3,596,593 shares through Longitude Venture Partners IV, L.P., where he is a managing member.
• The total beneficial ownership, including direct and indirect holdings, amounts to 5,300,094 shares.

Sentiment

Score: 8

Explanation: The direct purchase of a significant number of shares by a director indicates strong insider confidence, which is generally viewed positively by the market.

Positives

• A company director, Patrick G. Enright, purchased 5,882 shares of Class A Common Stock, indicating confidence in Vera Therapeutics' future prospects.
• The acquisition was made at a price of $42.50 per share, totaling approximately $250,035.

Negatives

• No negative information was disclosed in this filing.

Risks

• NA

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Patrick G. Enright, as a managing member of Longitude Prime Partners, LLC (general partner of Longitude Prime Fund, L.P.) and Longitude Capital Partners IV, LLC (general partner of Longitude Venture Partners IV, L.P.), has indirect beneficial ownership of shares held by these funds. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interests.

Stakeholder Impact

• Shareholders: May view the director's purchase as a positive signal, potentially increasing investor confidence and demand for the stock.
• Employees: Could interpret the insider buying as a sign of stability and positive future prospects for the company.

Key Dates

Recommendation

The direct purchase of company stock by a director, Patrick G. Enright, at a price of $42.50 per share, is a strong indicator of insider confidence. This action suggests that a key insider believes the company's stock is currently undervalued or has significant upside potential. Such insider buying often precedes positive company developments or improved financial performance, making it a compelling signal for investors to consider a 'buy' position.

Keywords

Vera Therapeutics, VERA, Insider Buying, Stock Purchase, Director Transaction, SEC Form 4, Equity Acquisition, Patrick G. Enright, Longitude Capital